1. Ossato A, Del Bono L, Gasperoni L, Inno A, Damuzzo V. Comparative efficacy of chemo-immunotherapy combination regimens in the frontline setting for NSCLC based on reconstructed patient data. J Chemother. Published online October 21, 2024. doi:10.1080/1120009X.2024.2417600
  2. Messori A, Romeo MR, Rivano M, Trippoli S. Real-world data on the effectiveness of TYRX and TauroPace for preventing CIED infections. Am J Cardiovasc Dis. 2024;14(4):220-229. Published 2024 Aug 25. doi:10.62347/DSHG1684
  3. Messori A, Trippoli S, Romeo MR, Fadda V, Rivano M, Spazio LD. Studying the Outcomes in Patients with Tricuspid Regurgitation Treated with Valve Repair or Valve Replacement: Interpreting the Survival Pattern on The Long Term by Application of Artificial Intelligence Methods. Rev Cardiovasc Med. 2024;25(6):223. Published 2024 Jun 20. doi:10.31083/j.rcm2506223
  4. Rivano M, Cancanelli L, Brunoro R, et al. Radiofrequency Ablation, Cryotherapy Ablation, or Pulsed-Field Ablation to Treat Paroxysmal Atrial Fibrillation Unresponsive to Pharmacological Treatments: Interpreting Efficacy Through Reconstruction of Individual Patient Data From Randomized Trials. Cureus. 2024;16(7):e65113. Published 2024 Jul 22. doi:10.7759/cureus.65113
  5. Gasperoni L, Del Bono L, Ossato A, Giunta EF, Messori A, Damuzzo V. A Head-to-Head Comparison of the First-Line Treatments for Locally Advanced or Metastatic Urothelial Cancer: Is There Still a Role for Chemotherapy?. Cancers (Basel). 2024;16(13):2400. Published 2024 Jun 29. doi:10.3390/cancers16132400
  6. Messori A, Fadda V, Rivano M, Trippoli S. Mitraclip Versus Medical Therapy or Surgery in Patients With Mitral Regurgitation: Long-Term Outcomes Determined by the Reconstruction of Individual Patient Data. Cureus. 2024;16(5):e60204. Published 2024 May 13. doi:10.7759/cureus.60204
  7. Messori A, Mamone D, Rivano M, Romeo MR, Vaiani M, Trippoli S. Pulsed-field ablation for paroxysmal atrial fibrillation: An indirect comparison of effectiveness among three proprietary devices conducted in the absence of randomized trials. Int J Cardiol. 2024;406:132025. doi:10.1016/j.ijcard.2024.132025
  8. Ossato A, Gasperoni L, Del Bono L, Messori A, Damuzzo V. Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival. Cancers (Basel). 2024;16(3):557. Published 2024 Jan 28. doi:10.3390/cancers16030557
  9. Rivano M, Mengato D, Chiumente M, Messori A. Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect Comparisons. Hematol Rep. 2023;15(4):670-683. Published 2023 Nov 26. doi:10.3390/hematolrep15040068
  10. Messori A, Rivano M, Chiumente M, Mengato D. Tislelizumab plus chemotherapy vs. pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials. Chin Clin Oncol. 2023;12(5):50. doi:10.21037/cco-23-26
  11. Ossato A, Mengato D, Chiumente M, Messori A, Damuzzo V. Progression-Free and Overall Survival of First-Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens. Cancers (Basel). 2023;15(7):2029. Published 2023 Mar 29. doi:10.3390/cancers15072029
  12. Messori A, Damuzzo V, Rivano M, et al. Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses. Cancers (Basel). 2023;15(6):1633. Published 2023 Mar 7. doi:10.3390/cancers15061633
  13. Messori A, Rivano M, Mengato D, Chiumente M. Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody. Cureus. 2022;14(12):e33169. Published 2022 Dec 31. doi:10.7759/cureus.33169
  14. Cancanelli L, Rivano M, Di Spazio L, Chiumente M, Mengato D, Messori A. Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments. Hematol Rep. 2023;15(1):57-65. Published 2023 Jan 13. doi:10.3390/hematolrep15010006
  15. Messori A, Chiumente M, Mengato D. Chimeric Antigen Receptor T Cells in Large B-Cell Lymphoma: Analysis of Overall Survival Based on Reconstructed Patient-Level Data. Clin Ther. 2022;44(12):1626-1632. doi:10.1016/j.clinthera.2022.11.002
  16. Damuzzo V, Rivano M, Baldo P, et al. Applicazione dell’intelligenza artificiale per un precoce confronto di efficacia tra nuovi farmaci oncologici [Application of artificial intelligence for an early comparison of efficacy between new cancer drugs.]. Recenti Prog Med. 2022;113(11):680-687. doi:10.1701/3907.38896
  17. Messori A, Rivano M, Cancanelli L, et al. The “One-to-Many” Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma. Cureus 14(8): e28369
  18. Rivano M, Cancanelli L, Di Spazio L, Mengato D, Chiumente M, Messori A. Survival with novel hormonal therapies in patients with nonmetastatic castration-resistant prostate cancer: indirect comparison of three randomized phase-III trials [published online ahead of print, 2022 Sep 9]. World J Urol. 2022;
  19. Ossato A, Damuzzo V, Baldo P, Mengato D, Chiumente M, Messori A. Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data [published online ahead of print, 2022 Aug 3]. Cancer Med. 2022;10.1002/cam4.5067.
  20. Cancanelli L, Mengato D, Di Spazio L, Rivano M, Chiumente M, Messori A. Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy. Int J Clin Pharmacol Ther. 2022;60(1):32-35.
  21. Messori A, Caccese E. Treatments for relapsed-refractory diffuse large B-cell lymphoma: comparison of overall survival outcomes observed with four novel agents. Eur Rev Med Pharmacol Sci. 2022;26(13):4666-4670.
  22. Messori A, Trippoli S. Current treatments for inoperable mesothelioma: indirect comparisons based on individual patient data reconstructed retrospectively from 4 trials [published online ahead of print, 2022 Apr 12]. J Chemother. 2022;1-5.
  23. Mengato D, Cancanelli L, Di Spazio L, Rivano M, Chiumente M, Messori A. Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy. Int J Clin Pharmacol Ther. 2022;60(8):370-372.
  24. Messori A. Lutetium in prostate cancer: Reconstruction of patient-level data from published trials and generation of a multi-trial Kaplan-Meier curve. World J Methodol. 2022;12(3):107-112. Published 2022 May 20.
  25. Trippoli S, Di Spazio L, Chiumente M, Messori A. Medical Therapy, Radiofrequency Ablation, or Cryoballoon Ablation as First-Line Treatment for Paroxysmal Atrial Fibrillation: Interpreting Efficacy Through the Shiny Method. Cureus. 2022;14(2):e22645. Published 2022 Feb 27.
  26. Messori A. Synthetizing Published Evidence on Survival by Reconstruction of Patient-Level Data and Generation of a Multi-Trial Kaplan-Meier Curve. Cureus. 2021;13(11):e19422. Published 2021 Nov 9.